Shanghai Yizhong Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Shanghai Yizhong Pharmaceutical has been growing earnings at an average annual rate of 81.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 73.2% per year. Shanghai Yizhong Pharmaceutical's return on equity is 6.3%, and it has net margins of 32.6%.
Key information
81.1%
Earnings growth rate
86.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 73.2% |
| Return on equity | 6.3% |
| Net Margin | 32.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?
Aug 20
What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You
Jul 24Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance
Apr 15Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely
Mar 29Revenue & Expenses Breakdown
How Shanghai Yizhong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 282 | 92 | 155 | 29 |
| 31 Mar 24 | 337 | 136 | 161 | 25 |
| 31 Dec 23 | 360 | 162 | 153 | 22 |
| 30 Sep 23 | 349 | 169 | 145 | 20 |
| 30 Jun 23 | 365 | 186 | 154 | 14 |
| 31 Mar 23 | 294 | 167 | 118 | 9 |
| 31 Dec 22 | 236 | 143 | 101 | 8 |
| 30 Sep 22 | 170 | 120 | 73 | 5 |
| 30 Jun 22 | 76 | 69 | 29 | 7 |
| 31 Mar 22 | 38 | 32 | 22 | 11 |
| 31 Dec 21 | 4 | -4 | 18 | 13 |
| 30 Sep 21 | 0 | -27 | 16 | 18 |
| 30 Jun 21 | 0 | -24 | 13 | 19 |
| 31 Mar 21 | 0 | -22 | 13 | 17 |
| 31 Dec 20 | 0 | -22 | 12 | 18 |
| 31 Dec 19 | 0 | -315 | 144 | 179 |
| 31 Dec 18 | 0 | -13 | 7 | 14 |
Quality Earnings: 688091 has high quality earnings.
Growing Profit Margin: 688091's current net profit margins (32.6%) are lower than last year (51%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688091 has become profitable over the past 5 years, growing earnings by 81.1% per year.
Accelerating Growth: 688091's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688091 had negative earnings growth (-50.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (0.4%).
Return on Equity
High ROE: 688091's Return on Equity (6.3%) is considered low.